Navigation Links
Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
Date:1/20/2010

THE WOODLANDS, Texas, Jan. 20 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus.  LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load.  LX4211, dosed as a single agent, provided improvements in glycemic control, demonstrating statistically significant benefits in the primary and multiple secondary efficacy endpoints.

"Results from this important first trial of LX4211 in diabetic patients exceeded our expectations," said '/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies
2. STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine
3. Bionovo Announces Publication of Positive Results From the Phase 1B Clinical Trial of Bezielle (BZL101) for Metastatic Breast Cancer
4. Start of Phase II Study for Intranasal, Seasonal Influenza Vaccine deltaFLU
5. Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes
6. Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis
7. Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema
8. Results From Phase II Trial in Critical Care Medicine Showed Eritoran Tetrasodium (E5564) To Be Well Tolerated in Patients with Severe Sepsis
9. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
10. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
11. BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronies Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015 Cogentix Medical, Inc. (NASDAQ: ... urology market, will release financial results for the first quarter ... the market close on Monday, August 10, 2015. ... to discuss these results on Monday, August 10, 2015 at ... Kill , President and Chief Executive Officer, and Brett ...
(Date:7/29/2015)... Calif. , July 29, 2015  AcelRx ... pharmaceutical company focused on the development and commercialization ... and breakthrough pain, today announced that it will ... on Monday, Aug 3rd, 2015. AcelRx management will ... Eastern Time (1:30 p.m. Pacific Time) on Aug ...
(Date:7/29/2015)... MOUNTAIN VIEW, Calif. , July 29, 2015 /PRNewswire/ ... in the growth strategy of pharmaceutical firms in ... . The realization is that an effective working ... sales, pricing pressures and patent cliffs. Big pharma companies ... bolster returns. Logo - http://photos.prnewswire.com/prnh/20150724/241957LOGO ...
Breaking Medicine Technology:Cogentix Medical to Announce First Quarter Fiscal 2016 Results on August 10, 2015 2AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. 2AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. 3AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. 4Working Capital Management Seizes Priority in North American and European Pharma Industry 2Working Capital Management Seizes Priority in North American and European Pharma Industry 3Working Capital Management Seizes Priority in North American and European Pharma Industry 4
... Nov. 20 Smith & Nephew ( SNN, LSE: SN) ... technology development contract with the United States Department of Defense ... system intended to revolutionize the treatment of the limbs of ... Advanced Research Projects Agency (DARPA), the central research and development ...
... 19 In response to an ever-increasing number of ... involving 24 countries, was coordinated by INTERPOL and the ... to highlight the dangers of buying medicines online. , ... of arrests and the seizure of thousands of potentially ...
Cached Medicine Technology:Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 2Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 4International Operation Combats Online Supply of Counterfeit and Illegal Medicines 2
(Date:7/29/2015)... ... 2015 , ... The New Foundation AZ recently started a massive ... cost the 501(c) organization nearly $1 million, will both update the facilities’ design and ... it down to the studs,” said Geraldine Leary, the New Foundation AZ chief executive ...
(Date:7/29/2015)... ... 29, 2015 , ... National non-profit World T.E.A.M. Sports announced ... employee benefits and asset management, has joined as presenting sponsor for the inaugural ... Charlotte, North Carolina on October 2-4, 2015. , Hosted at the U.S. ...
(Date:7/29/2015)... Indiana (PRWEB) , ... July 29, 2015 , ... Indiana ... It is also the home of Zerorez Indianapolis, which plans to expand across ... late 2013. “2015 is our second full year in business and we should double ...
(Date:7/29/2015)... Antonio, TX (PRWEB) , ... July 29, 2015 ... ... by a board-certified gastroenterologist, has launched a chewable version of its EndoMune Jr. ... to be a tasty, all-natural supplement that children can enjoy to maintain a ...
(Date:7/29/2015)... TN (PRWEB) , ... July 29, 2015 , ... ... Value-Added Solutions Group, which Breckheimer oversees. In her role, Powers is responsible for ... Upon making the announcement, Breckheimer commented, “Gina’s track record as an effective leader ...
Breaking Medicine News(10 mins):Health News:The New Foundation AZ Renovates Residential Dorms for Youth in Crisis 2Health News:The New Foundation AZ Renovates Residential Dorms for Youth in Crisis 3Health News:MetLife Joins World T.E.A.M. Sports’ Adventure Team Challenge North Carolina as Presenting Sponsor 2Health News:MetLife Joins World T.E.A.M. Sports’ Adventure Team Challenge North Carolina as Presenting Sponsor 3Health News:Zerorez® Announces Plans to Roll Across Indiana—“The Crossroads of America.” 2Health News:Zerorez® Announces Plans to Roll Across Indiana—“The Crossroads of America.” 3Health News:EndoMune Advanced Probiotic adds Chewable Tablet for Kids to Product Line 2Health News:EndoMune Advanced Probiotic adds Chewable Tablet for Kids to Product Line 3Health News:Gina Powers Named Vice President & General Manager of ITW Dynatec 2Health News:Gina Powers Named Vice President & General Manager of ITW Dynatec 3
... stroke, irrespective of traditional vascular risk factors, according to ... partly heritable. However, the importance of genetic and environmental ... the Stroke Prevention Research Unit at the Radcliffe Infirmary, ... patients who had an ischaemic stroke or transient ischaemic ...
... shown that the chemical language with which neurons communicate ... developing nervous system. The findings suggest that modification of ... a wide range of brain disorders. ,In the ... of the journal Proceedings of the National Academy of ...
... Saha and collaborators have found that the genetically engineered ... sources could set the stage for a new, biobased ... chewing gum, toothpaste, mouthwash and other products. ... and even to some degree by the human body. ...
... Medical School Researchers are developing the first of the generation ... the hospital superbug MRSA that lives in the nose. ... by standard antibiotics because the bacteria have developed a resistance ... scheduled for testing in humans next year and may be ...
... medical park and a vaccine park in Chennai soon to ... for research into new vaccines, said Health Minister Anbumani Ramadoss. ... manufacture medical equipment for the country, the vaccine park will ... ,"The medical park will be built on 300 acres of ...
... A new study that takes a rare look at the ... settings shows that when older adults go to bed lonely, ... after waking the next morning. ,Elevated levels of ... other health problems when chronic -- actually cue the body ...
Cached Medicine News:Health News:Electrical Activity Alters Language Used By Nerve Cells 2Health News:Electrical Activity Alters Language Used By Nerve Cells 3Health News:India to set up medical and vaccine parks: Ramadoss 2Health News:Adults Who Go to Bed Lonely Get Stress Hormone Boost Next Morning 2Health News:Adults Who Go to Bed Lonely Get Stress Hormone Boost Next Morning 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: